Trial Profile

Phase1 trial for ABSK021 in patients with advanced malignancies and Tenosynovial Giant Cell Tumors.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Apr 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pimicotinib (Primary)
Indications Giant cell tumour of tendon sheath; Solid tumours
Focus Adverse reactions
Sponsors Abbisko Therapeutics

Most Recent Events

07 Apr 2020 According to an Abbisko Therapeutics media release, the company announced the completion of dosing of the first patient cohort.
16 Aug 2019 According to an Abbisko Therapeutics media release, the company has received regulatory approval from US FDA to initiate its Phase 1 trial for ABSK021
16 Aug 2019 According to a Abbisko Therapeutics media release, the company expects to start dosing patients shortly.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com